A Single-arm, Open-label, Multi-center, Phase Iv, Efficacy And Safety Study Of Sunitinib Malate In The Treatment Of Chinese Patients With Gastrointestinal Stromal Tumor After Disease Progression On Or Intolerance To Imatinib Mesylate
Phase of Trial: Phase IV
Latest Information Update: 29 May 2015
At a glance
- Drugs Sunitinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- Sponsors Pfizer
- 29 May 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 20 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 03 Apr 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Mar 2014 to 1 May 2014.